Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis

Managed Care Interface

Volumn 19, Issue 9, 2006, Pages 47-53

  Bullano, Michael F ^c   McNeeley, Brian J ^a   Yu, Yanni F ^d,f   Quimbo, Ralph ^a   Burawski, Lauren P ^e   Yu, Elaine B ^d,f   Woolley, J Michael ^b  

^a HEALTHCORE INC   (United States)

^b AMGEN INC   (United States)

^c ASTRAZENECA   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e PFIZER INC   (United States)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD COMPLEX; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG COST; DRUG DOSE REGIMEN; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; OUTPATIENT CARE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 33749160957     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Stern R, Wolfe F: Infliximab dose and clinical status: results of two studies in 1,642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-1545.
2. Harley CR, Frytak R, Tandon N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(suppl 6):136-143.
3. Abarca J, Malone DC, Armstrong EP, et al: Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538-542.
4. Gilbert TD, Smith D, Ollendorf DA: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study. BMC Musculoskelet Disord 2004;5:36.
5. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-383.
6. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases. J Clin Epidemiol 1992;45:613-619.
7. Stockl K, Jarrar M, Tandon N: Dosing patterns of anti-TNF therapy in patients with rheumatoid arthritis in a managed care setting. Disease Manage Health Outcomes 2004;12:189-196.
8. Bathon, JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593.
9. Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet 2001;358:903-911.
10. Rheumatoid arthritis and Remicade. Centocor, Inc., (www.remicade.com/ra/ index.jsp), July 2006.
11. Wong JB: Cost-effectiveness of antitumor necrosis factor agents. Clin Exp Rheumatol 2004;22(5 suppl 35):65-70.
12. Nuijten MJ, Engelfriet P, Duijn K, et al: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-1064.
13. Ollendorf DA, Massarotti E, Birbara C, et al: Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-393.
14. Den Broeder AA, Creemers MC, van Gestel AM, et al: Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) 2002;41:638-642.
15. Wolfe F, Michaud K, De Witt EM: Why results of clinical trials and observational studies of antitumor necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004;63 (suppl 2):13-17.